By: Benzinga
UPDATE: Cantor Fitzgerald Initiates Sucampo Pharmaceuticals with Buy Rating on Near-Term Excitement, Long-Term Value
In a report published Wednesday, Cantor Fitzgerald analyst Irina Rivkind initiated coverage on Sucampo Pharmaceuticals (NASDAQ: SCMP ) with a Buy rating and $9.00 price target. In the report, Rivkind noted, “Sucampo is a closely held gastroenterology- and ophthalmology-focused company whose key product, Amitiza, has a near-term catalyst in opioid-induced
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here